Literature DB >> 17890416

Acceptance of the use of diazepam rectal gel in school and day care settings.

Debbie Terry1, Juliann Paolicchi, Mary Karn.   

Abstract

This study was conducted to identify how often parents of children with epilepsy encounter barriers to the use of diazepam rectal gel in day care or school settings and how these barriers affect the child and family. Sixty-four parents completed an 18-item questionnaire documenting their experience with asking their child's school to administer diazepam rectal gel. No data regarding its actual use in the school was obtained. Forty-three parents (68%) had asked their school to administer diazepam rectal gel; 35 (81%) reported school agreement, and 8 (19%) reported refusal. In 5 of these refusals, the cited reason was legal concerns, and in 5 cases the refusal had some adverse effect on their family's life. Most children prescribed diazepam rectal gel do not encounter resistance to its use in school and day care settings. Barriers to its use are usually due to legal concerns and significantly affect the family's quality of life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17890416     DOI: 10.1177/0883073807306254

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  4 in total

1.  What Should We Prescribe for Acute Seizures When There Is No Intravenous Access?

Authors:  Jerzy P Szaflarski
Journal:  Epilepsy Curr       Date:  2016 May-Jun       Impact factor: 7.500

Review 2.  Medication Use in Schools: Current Trends, Challenges, and Best Practices.

Authors:  Susan M Butler; Elizabeth A Boucher; Jennifer Tobison; Hanna Phan
Journal:  J Pediatr Pharmacol Ther       Date:  2020 Jan-Feb

3.  Development of benzodiazepines for out-of-hospital management of seizure emergencies.

Authors:  Suresh K Agarwal; James C Cloyd
Journal:  Neurol Clin Pract       Date:  2015-02

Review 4.  Rescue therapies for seizure clusters: Pharmacology and target of treatments.

Authors:  Barry Gidal; Kamil Detyniecki
Journal:  Epilepsia       Date:  2022-09       Impact factor: 6.740

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.